Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 19;11(3):00723-2024.
doi: 10.1183/23120541.00723-2024. eCollection 2025 May.

The electronic nose in lung cancer diagnostics: a systematic review and meta-analysis

Eline G M Steenhuis  1 , Oke D Asmara  2 , Sharina Kort  3 , Mirell H G Papenhuijzen  4 , Nic J G M Veeger  5   6 , Michel M Van den Heuvel  7 , Wouter H Van Geffen  2
Affiliations

The electronic nose in lung cancer diagnostics: a systematic review and meta-analysis

Eline G M Steenhuis et al. ERJ Open Res. .

Abstract

Background: Lung cancer remains a leading cause of cancer-related deaths. Early-stage detection is pivotal for curative interventions, yet most cases are diagnosed at advanced stages. Noninvasive point-of-care diagnostic strategies are needed to reduce lung cancer mortality rates. We assess the potential of electronic nose (eNose) devices as a tool for lung cancer detection.

Study design and methods: All online available databases were searched. Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we reviewed studies using eNose for in vivo exhaled air analysis in lung cancer patients. Included patients had pathologically confirmed lung cancer, both non-small cell lung cancer and small cell lung cancer, in various stages. Primary outcomes were sensitivity, specificity, negative predictive value and area under the curve. Secondary outcomes evaluated eNose performance in distinguishing non-small cell lung cancer subtypes and small cell lung cancer. Additionally, a subgroup analysis was conducted to evaluate the efficacy of various commonly used sensors in this differentiation. The Quality Assessment of Diagnostic Accuracy Studies 2 tool was used for risk-of-bias assessment.

Results: We included 35 studies, comprising 4483 patients. Pooled sensitivity and specificity were 0.90 (95% CI 0.87-0.93) and 0.89 (95% CI 0.85-0.93), respectively. The median negative predictive value was 0.93 and the median area under the curve was 0.91. Both the likelihood of bias and concerns regarding applicability were minimal.

Interpretation: eNose devices hold promise as noninvasive, point-of-care tools for lung cancer diagnosis. Owing to the high sensitivity and negative predictive values and great ease of use, they could be valuable additions to the diagnostic toolbox. Further research and validation efforts are critical to maximise their impact on early lung cancer detection.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: S. Kort reports support for the present study from the eNose Company and grants from eNose Company. Conflict of interest: W.H. Van Geffen reports a leadership role with the European Respiratory Society and NVALT (Dutch Society of Respiratory Physicians); and there have been trials run by his department funded by Roche and MSD. Conflict of interest: The remaining authors have nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Flowchart of included and excluded studies. GC-MS: gas chromatography–mass spectrometry.
FIGURE 2
FIGURE 2
Risk of bias and applicability concerns: review authors’ judgements about each domain presented as percentages across included studies.
FIGURE 3
FIGURE 3
Risk of bias and applicability concerns: review authors’ judgements about each domain for each included study.
FIGURE 4
FIGURE 4
Sensitivity and specificity of the included studies. TP: true positives; FP: false positives; FN: false negatives; TN: true negatives.
See this image and copyright information in PMC

References

    1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74: 229–263. doi: 10.3322/caac.21834 - DOI - PubMed
    1. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature 2018; 553: 446–454. doi: 10.1038/nature25183 - DOI - PubMed
    1. Gijtenbeek RGP, Damhuis RAM, Groen HJM, et al. Nationwide real-world cohort study of first-line tyrosine kinase inhibitor treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer. Clin Lung Cancer 2020; 21: e647–e653. doi: 10.1016/j.cllc.2020.05.019 - DOI - PubMed
    1. Jacobsen MM, Silverstein SC, Quinn M, et al. Timeliness of access to lung cancer diagnosis and treatment: a scoping literature review. Lung Cancer 2017; 112: 156–164. doi: 10.1016/j.lungcan.2017.08.011 - DOI - PubMed
    1. Fruh M, de Ruysscher D, Popat S, et al. Small-cell lung cancer (SCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2019; 24: 99–105. doi: 10.1093/annonc/mdt178 - DOI - PubMed

LinkOut - more resources